{
    "nct_id": "NCT06792734",
    "official_title": "Phase 1A/1B Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas",
    "inclusion_criteria": "* must be age ≥18 years\n* must have a diagnosis of relapsed or refractory mature B cell lymphoma\n* must have measurable disease per response evaluation criteria in lymphoma (Lugano classification)\n* must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* must have a predicted life expectancy of ≥3 months\n* must agree to use adequate birth control throughout their participation and for 90 days following the last dose of BTM-3566\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* has primary CNS lymphoma\n* has ongoing toxicities from prior anti-cancer treatment > Grade 1\n* has symptomatic or uncontrolled neurologic disease (brain metastases, leptomeningeal disease, or spinal cord compression) not definitively treated with surgery or radiation\n* has received any anti-cancer therapy (including radiation of curative intent) <28 days prior to administration of BTM-3566\n* has current second malignancy at other sites (exceptions: non-melanomatous skin cancer, adequately treated in situ carcinoma, or indolent prostate cancer under observation).\n* is pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}